| MeSH term | MeSH ID | Detail |
|---|---|---|
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Central Serous Chorioretinopathy | D056833 | 1 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Candidiasis, Invasive | D058365 | 2 associated lipids |
| End Stage Liver Disease | D058625 | 1 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Scorpion Stings | D065008 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yamagami S et al. | Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506. | 1997 | Transplantation | pmid:9233699 |
| Neuhaus P et al. | Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. | 1995 | Transplantation | pmid:7530868 |
| Gathogo E et al. | Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. | 2016 | Transplantation | pmid:26413990 |
| Takeguchi N et al. | Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. | 1993 | Transplantation | pmid:7681229 |
| Bundick RV et al. | FK506 as an agonist to induce inhibition of interleukin 2 production. | 1992 | Transplantation | pmid:1374947 |
| Kasahara M et al. | Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. | 2001 | Transplantation | pmid:11211185 |
| Al-Uzri A et al. | Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). | 2001 | Transplantation | pmid:11579294 |
| Papadopoulos-Köhn A et al. | Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. | 2015 | Transplantation | pmid:25208324 |
| Jiang H et al. | Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. | 2002 | Transplantation | pmid:12085006 |
| Shapiro R et al. | Posttransplant diabetes in pediatric recipients on tacrolimus. | 1999 | Transplantation | pmid:10096540 |
| Heidt S et al. | Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. | 2008 | Transplantation | pmid:19005412 |
| Cooper MH et al. | Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. | 1994 | Transplantation | pmid:7509089 |
| Araki M et al. | Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. | 2006 | Transplantation | pmid:16477217 |
| Borger P et al. | Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. | 2000 | Transplantation | pmid:10798763 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Gillard P et al. | Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. | 2014 | Transplantation | pmid:24770614 |
| Bazerbachi F et al. | Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. | 2013 | Transplantation | pmid:23183776 |
| Tricot L et al. | Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. | 2005 | Transplantation | pmid:16371923 |
| Jin L et al. | Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats. | 2018 | Transplantation | pmid:29319618 |
| Maluccio M et al. | Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. | 2003 | Transplantation | pmid:12923450 |